THC Therapeutics, Inc. (THCT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerTHC Therapeutics, Inc. (THCT) trades at $0.0003. THC Therapeutics, Inc. focuses on the wellness industry, developing the dHydronator, a sanitizing herb dryer. The company, formerly Millennium Blockchain, Inc., aims to serve the cannabis and related markets. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for THCT: THCT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
THC Therapeutics, Inc. (THCT) Healthcare & Pipeline Overview
THC Therapeutics, Inc., operating in the wellness sector, develops the dHydronator, a sanitizing herb dryer targeting the cannabis, herb, flower, and tea leaf markets. The company faces competition and regulatory hurdles typical of the specialty drug manufacturing and cannabis-adjacent industries.
What Is the Investment Thesis for THCT?
THC Therapeutics, Inc. presents a speculative investment opportunity within the niche market of cannabis and herb processing equipment. The company's focus on the dHydronator, a sanitizing herb dryer, targets a specific need within the cultivation and processing workflow. Growth catalysts include potential partnerships with cannabis cultivators and distributors, as well as expansion into related markets such as herbal medicine and tea production. However, the company's small size, limited operating history, and OTC listing present significant risks. Key value drivers depend on successful product commercialization, market acceptance, and the ability to secure funding for expansion. The company's high beta of 7.53 indicates significant volatility, and its negative P/E ratio of -0.47 reflects current unprofitability.
Based on FMP financials and quantitative analysis
THCT Key Highlights
THC Therapeutics operates in the wellness industry, focusing on equipment for cannabis and herb processing.
- The company's primary product is the dHydronator, a sanitizing herb dryer.
- The company rebranded from Millennium Blockchain, Inc. in September 2018.
- THC Therapeutics is based in Las Vegas, Nevada, and was incorporated in 2007.
- The company has a market capitalization of $0.00B and a P/E ratio of -0.47.
Who Are THCT's Competitors?
THCT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are THCT's Key Strengths?
Specialized product (dHydronator) targeting a niche market.
- Focus on the growing cannabis and wellness industries.
- Potential for innovation in drying and sanitization technologies.
- Adaptability to related markets such as herbal medicine and tea processing.
What Are THCT's Weaknesses?
Small company size with limited resources.
- Limited operating history and market presence.
- Dependence on a single product (dHydronator).
- OTC listing with associated risks.
What Are the Key Risks for THCT?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from established equipment manufacturers.
- Regulatory changes in the cannabis industry.
- Technological obsolescence.
- Small company size with limited resources.
- OTC listing with associated risks.
What Are THCT's Competitive Advantages?
- Specialized product (dHydronator) addressing a specific need.
- First-mover advantage in the sanitizing herb dryer market.
- Potential for intellectual property protection through patents.
- Focus on a niche market (cannabis and related industries).
What Does THCT Do?
THC Therapeutics, Inc., established in 2007 and based in Las Vegas, Nevada, operates within the wellness industry, focusing on the development of specialized drying and sanitization equipment. Originally incorporated as Millennium Blockchain, Inc., the company rebranded in September 2018 to reflect its strategic shift towards the cannabis and related markets. Its primary product, the dHydronator, is designed to dry and sanitize freshly harvested cannabis, herbs, flowers, and tea leaves, addressing a critical need for efficient and hygienic processing in these sectors. The dHydronator aims to provide a solution for businesses seeking to optimize their drying processes while maintaining product quality and safety. The company's evolution from blockchain technology to wellness solutions highlights its adaptability and focus on emerging market opportunities. As a small company with one employee, THC Therapeutics faces challenges in scaling production and distribution, requiring strategic partnerships and efficient resource management to compete effectively in the market.
What Products and Services Does THCT Offer?
- Develops the dHydronator, a sanitizing herb dryer.
- Targets the cannabis cultivation and processing market.
- Offers a solution for drying and sanitizing freshly harvested cannabis, herbs, flowers, and tea leaves.
- Aims to improve the efficiency and hygiene of the drying process.
- Provides equipment for the wellness industry.
- Focuses on specialized drying and sanitization equipment.
How Does THCT Make Money?
- Sales of the dHydronator to cannabis cultivators and processors.
- Potential revenue from licensing the dHydronator technology.
- Future revenue from maintenance and support services for the dHydronator.
- Expansion into related markets such as herbal medicine and tea processing.
What Industry Does THCT Operate In?
THC Therapeutics, Inc. operates in the evolving landscape of the cannabis and wellness industries. The market for cannabis processing equipment is growing alongside the increasing legalization and commercialization of cannabis in various jurisdictions. This growth is fueled by the demand for efficient and standardized processing methods. The company faces competition from established equipment manufacturers and smaller, specialized firms. Key trends include the adoption of automated systems, the emphasis on product quality and safety, and the increasing focus on sustainable practices. THC Therapeutics aims to carve a niche by offering a sanitizing herb dryer, addressing the specific need for hygienic processing in the cannabis and related sectors.
Who Are THCT's Key Customers?
- Cannabis cultivators.
- Cannabis processors.
- Herbal medicine producers.
- Tea producers.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
THC Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for THC Therapeutics, Inc. stands at 12.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
THC Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Jacksboro, US. The company is led by CEO Scott A. Cox. THCT has traded publicly since 2017.
Insider Activity
4 transactions · 2 purchases, 0 sales, 2 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
THCT Financials
THCT Latest News
No recent news available for THCT.
THCT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for THCT.
Price Targets
Wall Street price target analysis for THCT.
THCT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for THCT; grades run from A+ (80-100) to F (below 30).
Leadership: Scott A. Cox
CEO
Scott A. Cox serves as the CEO of THC Therapeutics, Inc. As CEO, he is responsible for the overall strategic direction and operational management of the company, including the development and commercialization of the dHydronator product. His leadership is critical to the company's success in the competitive cannabis and wellness industries.
Track Record: With limited information available, it is difficult to assess Scott A. Cox's specific track record at THC Therapeutics, Inc. However, the company's rebranding and focus on the dHydronator product suggest a strategic shift under his leadership. The success of the company will depend on his ability to secure funding, establish partnerships, and drive sales of the dHydronator.
THCT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that THC Therapeutics, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial reports. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. This contrasts with NYSE/NASDAQ listings, which have stringent financial and governance requirements, offering investors greater transparency and protection.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other status.
- Low liquidity and high bid-ask spreads.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight.
- Higher volatility compared to exchange-listed stocks.
- Verify the company's registration and legal standing.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their experience.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company's focus on a specific product (dHydronator).
- Operating history since 2007.
- Presence in the growing cannabis and wellness industries.
- Company's efforts to develop and market the dHydronator.
What Investors Ask About THC Therapeutics, Inc. (THCT) — Healthcare
What does THC Therapeutics, Inc. do?
THC Therapeutics, Inc. operates in the wellness industry, focusing on the development and commercialization of the dHydronator, a sanitizing herb dryer. This product is designed for drying and sanitizing freshly harvested cannabis, herbs, flowers, and tea leaves.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing carries inherent risks.